BNT327 + gemcitabine + carboplatin

BNT327 + gemcitabine + carboplatin is an investigational combination regimen for cancer therapy comprising **BNT327**, a bispecific antibody targeting PD-L1 and VEGF-A, with the chemotherapeutic agents **gemcitabine** and **carboplatin**. BNT327 acts by blocking PD-L1, thereby enhancing T-cell-mediated immune response against tumor cells, and neutralizing VEGF-A, disrupting tumor angiogenesis and the immunosuppressive tumor microenvironment. Gemcitabine is a nucleoside analog inhibiting DNA synthesis, and carboplatin is a platinum-based agent causing DNA crosslinking and apoptosis. The primary indication for this combination is as first-line therapy in **extensive-stage small cell lung cancer (ES-SCLC)**, with clinical trials also exploring use in other solid tumors and advanced cancers. The combination has demonstrated a high overall response rate and disease control with an acceptable safety profile in phase 2 trials[1][3][5].

Other names

PM8002 + gemcitabine + carboplatin